New Migraine Treatment Prevents Pain Progression

April 10, 2020


AXS-07 showed statistical significance for migraine pain freedom at 90 minutes, and at every time point after.

FDA Approves Ubrogepant for Acute Migraine in Adults

December 24, 2019


The oral CGRP antagonist becomes the first in its class approved for the indication.

FDA Approves Lasmiditan for Adult Migraine Attacks

October 11, 2019


The oral therapy showed benefit in reducing symptoms and migraine-related pain, as well as aura, within 2 hours of administration.

Excessive Caffeine Intake Could Trigger Migraines

August 08, 2019


Drinking more than 3 servings of caffeinated beverages per day was associated with an increase in migraine headaches.

Rimegepant Eliminates Migraine Pain, Reduce Symptoms in Clinical Trial

July 11, 2019


Rimegepant (rimegepant Zydis), which is a novel therapy for treatment of acute migraines, was found to reduce bothersome suymptoms and eliminate pain in a phase 3 clinical trial.

FDA Approves Galcanezumab as First Episodic Cluster Headache Drug

June 05, 2019


The approval is based on the findings of a 106-adult patient trial which assessed mean weekly headache episodes.

Common Causes of Our Diagnostic Errors

April 03, 2019


Overconfidence, anchoring errors, biases, and other factors have all led to misdiagnoses at points in my internal medicine career.

FDA Issues CRL for Rizaport Acute Migraine Treatment

April 02, 2019


The Complete Response Letter highlights issues in the Chemistry, Manufacturing, and Controls section of the application.

Study Finds Strong Association Between Dry Eye Disease and Migraines

March 13, 2019


While the diseases appear to be unrelated, there may be underlying factors that link them together.

FDA Accepts NDA for Investigational Insomnia Drug Lemborexant

March 11, 2019


An FDA decision on the application is expected by December 27, 2019.